Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FPI 2265

Next Previous
X
Search
Drug Profile

FPI 2265

Alternative Names: 225Ac-PSMA I&T; Ac-PSMA I&T - Fusion Pharmaceuticals; Ac225-PSMA - Fusion Pharmaceuticals; FPI-2265

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RadioMedix
  • Developer Fusion Pharmaceuticals
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Prostate cancer

Most Recent Events

  • 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
  • 09 Apr 2024 Interim efficacy and adverse event data from the phase II TATCIST trial in Prostate cancer released by Fusion Pharmaceuticals
  • 20 Mar 2024 Fusion Pharmaceuticals completes enrolment in the TATCIST trial for Prostate cancer in USA (NCT05219500)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top